Trials / Completed
CompletedNCT00189969
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 32 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the take rate (formation of a typical postvaccinal lesion)and the safety and immunogenicity of the smallpox vaccine Elstree-BN.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Elstree-BN |
Timeline
- Start date
- 2003-09-01
- Completion
- 2006-02-01
- First posted
- 2005-09-19
- Last updated
- 2006-04-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00189969. Inclusion in this directory is not an endorsement.